Our laboratory investigates the regulatory mechanisms underlying tumor-specific CD8 T cell dysfunction in the context of solid tumors. Cancer cells express mutated proteins that are distinct from the proteins in normal cells. These are known as tumor-specific antigens. Over a century ago, scientists reasoned that our immune system should be able to recognize these mutated proteins as foreign and eliminate cancer cells. However, although tumor-specific T cells are found within human tumors, they are not functional and allow cancers to grow unimpeded.
Andrea Schietinger, PhD
Assistant Member, Immunology Program, SKI
Research FocusCancer Immunologist Andrea Schietinger investigates immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy.
EducationPharmD, University of Hamburg, PhD, University of Chicago, Chicago, IL and University of Munich, Germany
- Schietinger A and Greenberg PD. “Tolerance and Exhaustion: Defining Mechanisms of T cell dysfunction.” (2014) Trends in Immunology, 35(2):51-60.
- Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin CP, Zal T, and Schreiber H. “Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.” (2014) Oncoimmunology, 2013 Nov 1;2(11):e26677.
- National Cancer Institute K99/R00 Award
- Josie Robertson Investigator Award
- V Foundation for Cancer Research Award
- William and Ella Owens Medical Research Foundation Award
- Cancer Research Institute Irvington Fellowship